Want to see SGMOQ full AI Analyst Report?
SGMOQ Stock Chart & Stats
$0.06
>-$0.01(-10.96%)
At close: 4:00 PM EDT
$0.06
>-$0.01(-10.96%)
Day’s Range― - ―
52-Week Range$0.03 - $0.77
Previous CloseN/A
Volume4.35M
Average Volume (3M)7.65M
Market Cap
$72.50M
Enterprise Value$87.94
Total Cash (Recent Filing)$27.59M
Total Debt (Recent Filing)$19.33M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$9.90M
Bulls Say, Bears Say
Bulls Say
ST-920 Regulatory PathwayFDA alignment reduces uncertainty around the ST-920 approval strategy and removes the need for an additional confirmatory trial, potentially shortening development requirements if the company or an acquirer completes the submission.
Durable Clinical ResponseLong-term biomarker persistence and sustained independence from enzyme replacement therapy support the durability of ST-920’s therapeutic effect, strengthening its clinical differentiation and potential attractiveness to strategic developers.
Pipeline And Platform ProgressProgress across neurology programs and platform technologies preserves scientific optionality beyond Fabry disease. Site activation and completed toxicology represent concrete steps toward future clinical development and strategic partnering.
Bears Say
Chapter 11 RestructuringBankruptcy and court-supervised asset sales indicate severe financial distress and can disrupt operations, employee retention, development continuity, and control of core programs, leaving outcomes for the remaining business highly uncertain.
Persistent Cash BurnSustained cash consumption means Sangamo cannot currently fund operations from internally generated resources. Continued development therefore depends on asset sales, financing, or partners, increasing execution risk and limiting strategic flexibility.
Negative Equity And LossesNegative equity, declining revenue, and large operating and net losses show that the current revenue base is far below the cost structure. This weak financial foundation raises dilution, creditor, and long-term viability risks.
Sangamo Therapeutics News
SGMOQ FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was $0.03 and its highest was $0.77 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is $72.50M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 72 days.
How were Sangamo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Sangamo Therapeutics overvalued?
According to Wall Street analysts Sangamo Therapeutics’s price is currently Overvalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,288,850 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Currently, no hedge funds are holding shares in SGMOQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sangamo Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 321.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.41%
Trailing 12-Months
Company Description
Sangamo Therapeutics
Sangamo Therapeutics (SGMO) is a clinical-stage biotechnology company focused on developing genomic medicine therapies. The company’s work centers on gene regulation and gene editing approaches, including zinc finger protein (ZFP) technology, to create potential treatments for serious genetic diseases and other conditions. Sangamo’s activities primarily span research and development, clinical advancement of its pipeline, and partnering its platform technologies with other biopharmaceutical companies.
SGMOQ Company Deck
SGMOQ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.View all SGMOQ earnings summariesTechnical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
0.94% Insiders
5.59% Mutual Funds
0.10% Other Institutional Investors
93.36% Public Companies and
Individual Investors